DOP023 Predictors of clinical and endoscopic response with vedolizumab for the treatment of moderately-severely active ulcerative colitis: results from the US VICTORY consortium.
暂无分享，去创建一个
B. Sands | C. Siegel | W. Sandborn | E. Loftus | P. Dulai | B. Boland | J. Colombel | A. Swaminath | M. Luo | G. Kochhar | S. Kane | D. Hudesman | D. Lukin | B. Shen | K. Sultan | R. Hirten | K. Lasch | K. Chaudrey | J. Koliani-Pace | M. Parikh | E. Shmidt | J. Hartke | P. Chilukuri | J. Meserve | M. Bohm | S. Singh | M. Barocas